TGA MDMA Australia: New 2026 Framework Expands Access and Updates Rules for Therapists

The Therapeutic Goods Administration (TGA) has released a significant update to the regulatory framework for MDMA-assisted therapy in Australia. Since July 1, 2023, authorised psychiatrists have been able to prescribe MDMA for post-traumatic stress disorder (PTSD) outside of clinical trials. However, procedural and practical challenges emerged during the program’s implementation. Consequently, the TGA undertook a review and has now issued four key recommendations to refine the Authorised Prescriber (AP) scheme. These updates are designed to balance facilitating appropriate access with ensuring strong safeguards are in place to protect patient safety.

The Original Framework: A Historic Step

In February 2023, the TGA made a landmark decision to reschedule MDMA from Schedule 9 (Prohibited Substance) to Schedule 8 (Controlled Drug) for the specific treatment of PTSD, effective July 1, 2023. This made Australia the first country to formally recognise MDMA as a prescription medicine for a psychiatric condition.

Key elements of the 2023 framework included:

• Prescribers: Only psychiatrists could prescribe, and they had to be specifically authorised under the TGA’s Authorised Prescriber scheme.
• Approval Process: Psychiatrists needed to develop a treatment protocol, obtain approval from a registered Human Research Ethics Committee (HREC), and then receive TGA authorisation.
• Indications: MDMA was only approved for PTSD, and psilocybin for treatment-resistant depression.
• Unapproved Status: Products containing these substances are not included in the Australian Register of Therapeutic Goods (ARTG), meaning they remain unapproved therapeutic goods.

The 2026 TGA Recommendations: What Has Changed?

The TGA has issued four recommendations to clarify and refine the AP scheme, following consultation with over 80 stakeholders.

Recommendation 1: Psychiatrist Competency

• The Change: Psychiatrists must now demonstrate competency in psychedelic-assisted therapy through one of two pathways: prior involvement in clinical trials or supervised practice under an experienced Authorised Prescriber psychiatrist.
• The Reason: Few psychiatrists have clinical trial experience, so requiring trial experience alone would have restricted access. The Royal Australian and New Zealand College of Psychiatrists (RANZCP) training framework now provides a benchmark for competency.

Recommendation 2: The Therapy Team (“Dyad”)

• The Change: Treatment must be administered by a “therapy dyad” consisting of the AP psychiatrist and at least one other registered healthcare practitioner. This can include an endorsed clinical psychologist, a physician, a mental health nurse, or an occupational therapist.
• The Reason: Broadening the range of therapists aims to improve access, particularly in rural and regional areas, address workforce shortages, and support culturally appropriate care.

Controversy and Concern:
This change has sparked significant debate. The Australian Association of Psychologists (AAPi) has strongly criticised the new rules, stating they exclude approximately 70% of psychologists from providing psychedelic-assisted therapy. Clinical psychologist Shai Hipperson has also warned that without standardised training benchmarks, the changes could endanger vulnerable patients.

Recommendation 3: Prescriber Oversight

• The Change: The AP psychiatrist is responsible for patient screening and ongoing informed consent and must be present in-person while the psychedelic is being administered to respond to any immediate issues or adverse events.
• The Flexibility: Continuous presence throughout the full dosing day is not required, which the TGA says “preserves a degree of flexibility to support service accessibility”. However, the psychiatrist remains responsible for the patient and treating team.

Recommendation 4: Treatment Site Standards

• The Change: Clear minimum standards for treatment sites have been established. Sites must have emergency resuscitation capability, secure storage for Schedule 8 medicines, and be located within 15 minutes of an accredited healthcare facility with an emergency department.
• The Reason: Treatment is no longer restricted to traditional hospital settings. Less overtly clinical settings can improve patient comfort and outcomes and are more accessible for patients in rural and regional areas, including First Nations people.

Clinical Evidence, Safety, and Access

A Strong Safety Record

According to aggregated data reviewed by Australian regulators, no serious adverse events have been reported under the Authorised Prescriber scheme since December 2025. This real-world safety record reinforces confidence in the regulated program.

Clinical Practice Guideline

The world’s first clinical practice guideline on MDMA-assisted psychotherapy (MDMA-AP) for PTSD was developed by Monash University and endorsed by the NHMRC. It does not recommend MDMA-AP as part of routine care but recommends its use be limited to adults over 18 with PTSD symptoms for at least six months who have failed first-line evidence-based treatments.

Access and Costs

• Patient Numbers: About 164 patients have received MDMA-assisted therapy outside of clinical trials, and 40 psychiatrists hold approvals.
• Cost: The treatment is expensive, with courses costing around $20,000 to $30,000. However, coverage is expanding through Medibank, the Department of Veterans’ Affairs (DVA), the NDIS, and WorkCover programs.

Conclusion

The TGA’s 2026 recommendations represent a significant evolution of Australia’s pioneering MDMA therapy framework. The changes aim to expand access by broadening the therapist pool and allowing treatment in more diverse settings while maintaining strong safety safeguards. However, the new rules have sparked debate about patient safety and the exclusion of many psychologists. With a strong real-world safety record and growing reimbursement support, MDMA-assisted therapy continues to develop as a new frontier in mental health treatment. This guide is for educational purposes only and does not constitute legal or medical advice.